

[Doxorubicin](#)

Not recommended as an essential medicine

Section:

[8. Immunomodulators and antineoplastics](#) [8.2. Antineoplastics and supportive medicines](#) [8.2.1. Cytotoxic medicines](#)

ATC codes: [L01DB01](#)

EMLc

Indication

Unspecified malignant neoplasms of ill-defined or unspecified sites ICD11 code: [2D9Z](#)

INN

Doxorubicin

Medicine type

Chemical agent

List type

Complementary

Formulations

Parenteral > General injections > IV: 10 mg in vial (hydrochloride) ; 50 mg in vial (hydrochloride)

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1982 ([TRS 685](#))

Changed in 2002 ([TRS 914](#))

Changed in 2003 ([TRS 920](#))

Changed in 2007 ([TRS 950](#))

Removed in 2015 ([TRS 994](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Tags

Cancer

Wikipedia

[Doxorubicin](#)

DrugBank

[Doxorubicin](#)

Summary of evidence and Expert Committee recommendations

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of doxorubicin was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for doxorubicin for more information.